Not long ago, life was very difficult not only in Uganda but also in the entire world because of the Covid-19 outbreak that did hit the world. There was tension and panic all over and things were worse in Uganda as the government imposed a lockdown and a curfew.
The good thing is that things started going back to normal and people started enjoying life again but unfortunately for Ugandans, they were hit again, this time by another dangerous disease known as Ebola.
For a period of time now, Ugandans have been living in fear because of the Ebola virus but today, anxiety was raised high after 1,200 experimental Ebola Vaccine doses finally arrived in the country to be used in scientific trials.
According to K24 TV, the ebola vaccine doses which were received in Uganda are designed to work against the Sudan strain of the Ebola virus that has been affecting the country for weeks now.
Content created and supplied by: AbubakarIDD (via Opera
News )
Opera News is a free to use platform and the views and opinions expressed herein are solely those of the author and do not represent, reflect or express the views of Opera News. Any/all written content and images displayed are provided by the blogger/author, appear herein as submitted by the blogger/author and are unedited by Opera News. Opera News does not consent to nor does it condone the posting of any content that violates the rights (including the copyrights) of any third party, nor content that may malign, inter alia, any religion, ethnic group, organization, gender, company, or individual. Opera News furthermore does not condone the use of our platform for the purposes encouraging/endorsing hate speech, violation of human rights and/or utterances of a defamatory nature. If the content contained herein violates any of your rights, including those of copyright, and/or violates any the above mentioned factors, you are requested to immediately notify us using via the following email address operanews-external(at)opera.com and/or report the article using the available reporting functionality built into our Platform
See More
COMMENTS